Art. -Nr.: HY-153521

CCT374705

Kundenbewertung

Based on 1 Customer Validation

CCT374705 is an orally active BCL6 inhibitor (IC₅₀ = 4.8 nM) with potent antiproliferative effects in vitro. CCT374705 effectively inhibits tumor growth in a lymphoma xenograft mouse model.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.29%
CAS. Nr.: 2640647-90-9
Formel: C₂₁H₁₈ClF₃N₄O₂
Molecular Weight:450.84

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

CCT374705 Chemical Structure

CAS. Nr.: 2640647-90-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HT	GI₅₀	545 nM Compound: 17; CCT374705	Antiproliferative activity against human HT cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay Antiproliferative activity against human HT cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay	[PMID: 37026591]
KARPAS-422	GI₅₀	14.9 nM Compound: 17; CCT374705	Antiproliferative activity against human KARPAS-422 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay Antiproliferative activity against human KARPAS-422 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay	[PMID: 37026591]
OCI-Ly1	GI₅₀	38.5 nM Compound: 17; CCT374705	Antiproliferative activity against human OCI-Ly1 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay Antiproliferative activity against human OCI-Ly1 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay	[PMID: 37026591]
OCI-Ly3	GI₅₀	1850 nM Compound: 17; CCT374705	Antiproliferative activity against human OCILY3 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay Antiproliferative activity against human OCILY3 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay	[PMID: 37026591]
SUD4	GI₅₀	1380 nM Compound: 17; CCT374705	Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition incubated for 14 days by luminescence based CellTiter Glo assay	[PMID: 37026591]

In Vitro

CCT374705 inhibits BCL6 with an IC₅₀ of 4.8 nM^[1].
CCT374705 (14 d) has potent antiproliferative activity in BCL-dependent cell lines – OCl-Ly1 and Karpas 422, with sub-100 nM GI₅₀^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CCT374705 (1 mg/kg, i.v. or 5 mg/kg, p.o.) has good oral bioavailability, low total clearance and plasma protein binding, thus results in the highest free concentrations in Balb/C mice^[1].
CCT374705 (50 mg/kg, p.o., 35 d) results in a significant increase in ARID3A mRNA expression in Karpas 422 tumor xenograft mice model, indicating the modulation of BCL6 activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2640647-90-9
Appearance Solid
Molecular Weight 450.84
Formel C₂₁H₁₈ClF₃N₄O₂
Color White to off-white
SMILES

O=C1N(C)C2=C(C=C(NC3=C(Cl)C(F)=NC=C3)C=C2)C4=C1OCC(F)(F)[C@H](C5CC5)N4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (221.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2181 mL

11.0904 mL

22.1808 mL

5 mM

0.4436 mL

2.2181 mL

4.4362 mL

10 mM

0.2218 mL

1.1090 mL

2.2181 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.55 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Harnden AC, et al. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones. J Med Chem. 2023 Apr 27;66(8):5892-5906. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2181 mL	11.0904 mL	22.1808 mL	55.4520 mL
	5 mM	0.4436 mL	2.2181 mL	4.4362 mL	11.0904 mL
	10 mM	0.2218 mL	1.1090 mL	2.2181 mL	5.5452 mL
	15 mM	0.1479 mL	0.7394 mL	1.4787 mL	3.6968 mL
	20 mM	0.1109 mL	0.5545 mL	1.1090 mL	2.7726 mL
	25 mM	0.0887 mL	0.4436 mL	0.8872 mL	2.2181 mL
	30 mM	0.0739 mL	0.3697 mL	0.7394 mL	1.8484 mL
	40 mM	0.0555 mL	0.2773 mL	0.5545 mL	1.3863 mL
	50 mM	0.0444 mL	0.2218 mL	0.4436 mL	1.1090 mL
	60 mM	0.0370 mL	0.1848 mL	0.3697 mL	0.9242 mL
	80 mM	0.0277 mL	0.1386 mL	0.2773 mL	0.6932 mL
	100 mM	0.0222 mL	0.1109 mL	0.2218 mL	0.5545 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CCT374705

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CCT374705

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CCT374705 Related Classifications

HY-153521 Related Classifications